KJHP
DFTX

K.J. Harrison & Partners’s Definium Therapeutics DFTX Stock Holding History

K.J. Harrison & Partners’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,433
Closed -$14K – 229
2022
Q2 		$14K Hold
1,433
– – ﹤0.01% 207
2022
Q1 		$24K Hold
1,433
– – ﹤0.01% 281
2021
Q4 		$30K Hold
1,433
– – ﹤0.01% 324
2021
Q3 		$52K Hold
1,433
– – 0.01% 307
2021
Q2 		$75 Buy
+1,433
New +$75.2K 0.01% 283

Other funds holding DFTX

DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

K.J. Harrison & Partners's DFTX Position: Q3 2022 in Review

K.J. Harrison & Partners sold out of Definium Therapeutics (DFTX) in Q3 2022, closing a stake of 1,433 shares — an estimated $14K sold.

K.J. Harrison & Partners first reported a position in DFTX in Q2 2021 and held it in 5 quarters. The position peaked at $52K in Q3 2021. 101 funds tracked by Wall St. Rank hold DFTX as of Q3 2022.

  • K.J. Harrison & Partners reported no remaining Definium Therapeutics position as of Q3 2022 after selling out during the quarter.
  • K.J. Harrison & Partners sold 1,433 Definium Therapeutics shares in Q3 2022, an estimated $14K.
  • K.J. Harrison & Partners first reported a position in Definium Therapeutics in Q2 2021 and held it in 5 quarters.
  • K.J. Harrison & Partners's Definium Therapeutics position peaked at $52K in Q3 2021.
  • 101 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2022.

Based on K.J. Harrison & Partners's 13F filing for Q3 2022, filed 21 Oct 2022.